Intelligence · INN directory
Oncology Drugs Directory
Anticancer agents, immuno-oncology biologics, targeted therapies, and oncology pipeline compounds tracked across FDA, EMA, and congress readouts.
Quick answer
Oncology drugs: NovaPharmaNews indexes 40 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. Anticancer agents, immuno-oncology biologics, targeted therapies, and oncology pipeline compounds tracked across FDA, EMA, and congress readouts.
-
palbociclib
IBRANCE Pfizer Australia Pty Ltd
L01EF01 -
adalimumab
ABRILADA Pfizer Australia Pty Ltd
L04AB04 -
anti-melanoma mab fragments
TECNEMAB K1
V09IA02 -
autologous glioma tumor cell lysates (inactivated)
SITOIGANAP
L01XX -
belantamab mafodotin
BLENREP
L01FX15 -
ciltacabtagene autoleucel
CARVYKTI
L01XL05 -
dabrafenib
TAFINLAR Novartis Pharmaceuticals
L01EC02 -
datopotamab deruxtecan
DATOPOTAMAB DERUXTECAN DAIICHI SANKYO
L01FX35 -
idecabtagene vicleucel
ABECMA
L01 -
infliximab
INFLECTRA Pfizer Australia Pty Ltd
L04AB02 -
talimogene laherparepvec
IMLYGIC
L01XX51 -
teclistamab
TECVAYLI
L01F -
dabrafenib mesilate
TAFINLAR INITIAL APPROVAL
-
ianalumab
-
prolia
-
remicade
Frequently asked questions
How many oncology drugs are in the directory?
40 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.
How are drugs assigned to a therapeutic area?
Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.
Where does regulatory data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence.